Antinociceptive Impact of Intrathecal Injection of Genetically Engineered Human Bone Marrow Stem Cells Expressing the Human Proenkephalin Gene in a Rat Mannequin of Bone Most cancers Ache.
Ache Res Manag. 2017;2017:7346103
Authors: Solar Y, Tian Y, Li H, Zhang D, Solar Q
Background. This examine aimed to research using human bone marrow mesenchymal stem cells (hBMSCs) genetically engineered with the human proenkephalin (hPPE) gene to deal with bone most cancers ache (BCP) in a rat mannequin. Strategies. Main cultured hBMSCs have been passaged and modified with hPPE, and the cell suspensions (6 × 106) have been then intrathecally injected right into a rat mannequin of BCP. Paw mechanical withdrawal threshold (PMWT) was measured earlier than and after BCP. The results of hPPE gene switch on hBMSC bioactivity have been analyzed in vitro and in vivo. Outcomes. No modifications have been noticed within the floor phenotypes and differentiation of hBMSCs after gene switch. The hPPE-hBMSC group confirmed improved PMWT values on the ipsilateral facet of rats with BCP from day 12 postoperatively, and the analgesic impact was reversed by naloxone. The degrees of proinflammatory cytokines equivalent to IL-1? and IL-6 have been ameliorated, and leucine-enkephalin (L-EK) secretion was augmented, within the hPPE-engineered hBMSC group. Conclusion. The intrathecal administration of BMSCs modified with the hPPE gene can successfully relieve ache attributable to bone most cancers in rats and is perhaps a probably therapeutic software for cancer-related ache in people.
PMID: 28286408 [PubMed – indexed for MEDLINE]